TRF2 is not frequently mutated in cancers, but it results up-regulated in a large panel of tumors [4–6], including breast cancer where accumulation of TRF2 has been reported to occur during transformation and progression ensuring telomere protection and indefinite lifespan maintenance [7, 8]. The gene discussed is TERF2; the disease is breast carcinoma.